Infection in the neutropenic and stem cell transplant patient

Current Opinion in Infectious Diseases

Volumn 12, Issue 4, 1999, Pages 355-358

  Klastersky, Jean ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIVIRUS AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FLUCONAZOLE; GANCICLOVIR; GLYCOPEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIPENEM; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; SULPERAZON; VANCOMYCIN;

BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; HUMAN; INFECTION; MYCOSIS; NEUTROPENIA; PREVENTION; PROPHYLAXIS; SHORT SURVEY; STEM CELL TRANSPLANTATION;

EID: 0032844316     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199908000-00008     Document Type: Short Survey

References (31)

1. Young SD, Feld R. Fever associated with chemotherapy-induced neutropenia: a review of current therapeutic approaches. Curr Opin Infect Dis 1998; 11:401-409.
2. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41 (Suppl. D):13-24.
3. Klastersky J. Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness. Curr Opin Oncol 1998; 10:284-290.
4. Larsson K, Björkstrand B, Ljungman P. Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation. Support Care Cancer 1998; 6:378-383.
5. Engels EA, Ellis CA, Supran SE, Schnid CH, Barza M, Schenkein DP, et al. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 1999, 28:256-266.
6. Winston DJ, Bartoni K, Bruckner A, Schiller GJ and Territo MC. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 1998; 26:576-583.
7. Hess U, Böhme C, Rey K, Senn HJ. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998; 6:402-409.
8. Marie JP, Marjanovic Z, Vekhoff A, Bouvet A, Chast F, Levy V, et al. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients. Support Care Cancer 1999; 7:89-94.
9. Koya R, Andersen J, Fernandez H, Goodman M, Spector N, Smith R, et al. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplant 1998; 21:923-926.
10. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16:1179-1187. A meta-analysis that clarifies the role of fluoroquinolones as a preventative measure in neutropenic patients.
11. Ruescher T, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82:2275-2281.
12. Bilgrami S, Feingold JM, Dorsky D, Edwards RL, Clive J, Tutschka PJ. Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21:591-595.
13. Elishoov H, Or R, Strauss N, Engelhard D. Nosocomial colonization, septicemia and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. Medicine 1998; 77:83-101.
14. Nucci M, Silveira MI, Spector N, Silveira F, Velasco E, Akiti T, et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998; 27:107-111.
15. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104:238-245.
16. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N, the Canadian Fluconazole Prophylaxis Study Group. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28:331-340.
17. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999; 28:250-255.
18. EORTC International Antimicrobial Therapy Cooperative Group. Empiric therapy in febrile granulocytopenic patients. Am J Med 1989; 86:668-672.
19. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-618.
20. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 105:478-483.
21. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-771. A pivotal prospective study suggesting that empiric therapy with antifungal agents is indicated in neutropenic patients with persistent neutropenia.
22. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-1396.
23. Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, et al. An EORTC International Multicenter Randomized Trial comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27:1406-1412.
24. Ribaud P, Chastang C, Latgé JP, Baffroy-Lafitte L, Parquet N, Devergie A, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28:322-330.
25. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098-1103.
26. Humar A, Wood S, Lipton J, Messner H, Meharchand J, McGeer A, et al. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants. Clin Infect Dis 1998; 26:606-610.
27. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21:597-605.
28. Reusser P. Current concepts and challenges in the prevention and treatment of viral infections in immunocompromised cancer patients. Support Care Cancer 1998; 6:39-45. This paper provides new concepts in understanding the pathogenesis of CMV infection in transplanted patients.
29. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997; 102:27-30.
30. Giles FJ. Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants. Clin Infect Dis 1998; 26:1282-1289. An excellent discussion of CSF usage in patients with leukemia and bone marrow or stem cell transplants.
31. Lyman GH, Kuderer NM, Balduccci L. Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia. Curr Opin Oncol 1998; 10:291-296.